Data Published for Medtronic's In.Pact Admiral DCB in De Novo In-Stent Restenosis


October 18, 2017—Findings from the IN.PACT Global study's de novo in-stent restenosis (ISR) imaging cohort were published by Marianne Brodmann, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2017;10:2113–2123). The study sought to evaluate the safety and effectiveness of the In.Pact Admiral drug-coated balloon (Medtronic) for the treatment of patients with de novo ISR.

As summarized in JACC: Cardiovascular Interventions, the IN.PACT Global study is an independently adjudicated prospective multicenter study that enrolled 1,535 patients with symptomatic atherosclerotic disease of the superficial femoral and/or popliteal arteries, including de novo ISR lesions. Patients enrolled in the prespecified ISR imaging cohort were evaluated for vessel patency and reintervention within the 12-month follow-up period.

This analysis included a total of 131 patients with 149 ISR lesions (mean age, 67.8 years). The mean lesion length in the cohort was 17.17 ± 10.47 cm, including 34% total occlusions and 59.1% calcified lesions.

The investigators reported that the 12-month Kaplan-Meier estimate of primary patency was 88.7%. The rate of clinically driven target lesion revascularization (CD TLR) at 12 months was 7.3%. The primary safety outcome, a composite of freedom from device- and procedure-related mortality through 30 days and freedom from major target limb amputation and CD TLR within 12 months, was 92.7%. There were no major target limb amputations, no deaths, and a low (0.8%) thrombosis rate.

These data demonstrated the safety and effectiveness of the In.Pact Admiral DCB in complex femoropopliteal lesions, including this challenging ISR subset, concluded the investigators in JACC: Cardiovascular Interventions.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.